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1. Introduction 
The following part is a general introduction to the field of influenza virus infection 
and vaccination, and the mucosal immunology of the upper aerodigestive tract. It is 
therefore not extensively cited.  
The majority of the adult population has an opinion of what an influenza virus 
infection or ”the flu” is, and they will most likely have experienced one or more 
influenza-like illnesses during their lifetime, with typical symptoms like fever, cough, 
nasal congestion, headache and myalgia (61). However, many of these febrile 
episodes referred to as influenza are often caused by other pathogens than the 
influenza virus (99). During the last years there has been a tremendous public interest 
in influenza virus infection, mainly because of the new subtypes of avian influenza 
virus that have infected humans, and the potential threat of a new pandemic influenza 
virus. 
1.1 Historical overview of influenza 
Influenza has been known for centuries, and causes seasonal epidemics in the 
Northern Hemisphere almost every winter.  
Hippocrates may provide the first report of what today is interpreted to be an 
influenza outbreak, in Greece in 412 BC (41). Since then there are numerous other 
reports that appear to describe influenza infection. The first description of what is 
believed to be epidemic influenza was in 1173 (10).  
The name of the virus is derived from the Italian word influentia, which is connected 
to the belief in 1300 that the disease was influenced by astrological constellations. 
The initial search in modern time for the aetiology of influenza started in the 
beginning of the 19th-century, and the bacteria Haemophilus influenza became first 
associated with the disease. During and after the influenza pandemic in 1918, an 
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intense search started, for the cause of influenza (4). The first virus was isolated in 
swine by Richard Shope in 1931 (81). In 1933 Wilson Smith published his article of 
the influenza virus isolated from humans (84). Today, we know that the influenza 
virus Shope isolated from swine in 1931 descended from the 1918 (H1N1) virus.  
There have been 3 (4 with the re-emergence of H1N1 in 1977) pandemics of 
influenza during the last 100 years, which in total have killed more than 50 million 
people world-wide. So far, the worst pandemic was in 1918, known as The Spanish 
Flu (H1N1) and this alone may have killed more than 40 million people. Later, in 
1957 came the Asian Flu (H2N2) and in 1968 the Hong Kong Flu (H3N2). In 1977 
the H1N1 virus re-emerged as the Russian Flu, and since then both the H1N1 and the 
H3N2 have been circulating in the human population.    
There is a common view among health authorities that a new influenza pandemic is 
imminent. In latter years there have been numerous reports and predictions about this 
threat (23). In the media we have all learned about the highly pathogenic avian 
influenza outbreaks in Asia (6). According to the latest update (WHO, April 2008) 
there have been 348 cases of laboratory-confirmed H1N5 avian influenza in humans 
and 216 deaths world-wide (107). Luckily, there has so far been very few cases of 
human to human spread of this avian influenza virus (110).  
1.2 The Influenza Virus 
Influenza viruses belong to the family Orthomyxoviridae, and are enveloped RNA 
viruses with a segmented genome. Influenza A and B viruses have eight gene 
segments, while the C virus has seven gene segments. They also differ in the 
antigenic properties of the internal proteins (matrix and nucleoproteins).  
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Characteristics Influenza A Influenza B Influenza C 
No. of gene segments 8 8 7 
Surface glycoproteins HA and NA 
(Haemagglutinin and 
Neuraminidase) 
HA and NA 
(Haemagglutinin and 
Neuraminidase) 
HEF  
(Haemagglutinin-
Esterase-Fusion) 
Host range Wide (humans, pigs, 
horses, whales, seals 
and birds) 
Humans (but also 
isolated from e.g.  
seals) 
Mainly humans, but 
also found in swine 
 
Table 1: Some major differences between the influenza viruses. From (22).  
 
Influenza virus C is genetically a relatively stable virus and is rarely isolated due to 
its low clinical significance. Infections with this virus give mild symptoms similar to 
the common cold. Most adults have antibodies against this virus, reflecting that 
infections with influenza virus C are common in childhood. The C virus differs from 
A and B viruses by having only one surface glycoprotein, namely the HEF protein. 
Influenza virus B is mainly a human pathogen, although it has been isolated from 
some other species, e.g. seals. It is a relatively stable virus and has caused local and 
epidemic outbreaks, but has not caused pandemic outbreaks. The annual influenza 
vaccine also contains influenza virus B antigens.  
It is only influenza A virus which causes pandemic influenza. Influenza A virus is 
found in a wide range of vertebrates, and has aquatic birds as its natural reservoir, 
where the influenza A infection unlike in humans is an asymptomatic intestinal 
infection (109). Both the type A and B viruses have 2 surface glycoproteins, the 
haemagglutinin (HA) and the neuraminidase (NA), but the variety in surface 
molecules in the A virus is one magnitude higher than in the B virus. The A viruses 
are therefore divided into subtypes based on genetic and antigenic variability. So far, 
16 serologically distinct HA and 9 NA have been identified in aquatic birds.  
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Figure 1: A diagrammatic representation of influenza A virus showing protein and genomic 
RNA complexes. HA, haemagglutinin; NA, neuraminidase; M1, M2, matrix proteins; NP, 
nucleoprotein; NS, non-structural proteins; PA, PB1, PB2, proteins involved in virus 
replication. From (25). Illustration reproduced with permission.  
1.2.1 Classification and nomenclature of influenza viruses 
The naming consensus of the influenza virus is as follows: Type of influenza virus 
(A, B or C) / Host (if not human) / Place of isolation / Strain number / Year, and for 
influenza A also the HA and NA subtype, abbreviated H and N. Example: 
A/duck/USSR/695/76 (H2N3) and C/Paris/1/67 (105). 
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1.2.2 Structure of the influenza virus 
Influenza A and B viruses are enveloped negative-sense single-stranded RNA viruses 
with 8 genome segments, coding for up to 11 viral gene products. Each genome 
segment is encapsulated by nucleoproteins (NP) to a ribonucleoprotein structure 
(RNP). The virus envelope consists of the host cell membrane, and incorporates 3 
viral encoded surface proteins. The haemagglutinin (HA) and the neuraminidase 
(NA) protrude from the surface with about 500 molecules per virus (54), while the 
M2 proteins are integrated into the membrane. These proteins are the most important 
antigens of the influenza A and B virus, regarding the adaptive immunity against 
influenza. The HA binds to sialic acid containing receptors at the cell membrane of 
the host cell, and the NA aids in viral exit from the cell. The M2 protein is an ionic 
channel that is important in modulating the pH in the virion.  
Underlying the lipid bilayer are approximately 3000 copies of the M1 protein (54), 
and within the matrix are the 8 segmented RNP complexes, together with the viral 
transcriptases; polymerase B1 (PB1), polymerase B2 (PB2) and PA, and probably 
low amounts of NS2 (NEP) (Reviewed in (22)). The functions of the different viral 
proteins are summarised in table 2, and the virus architecture is illustrated in figure 1. 
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Segment Encoded Protein Function 
1 PB2  Basic Polymerase Protein 2  
Part of the RNA polymerase complex. Transcriptase. Generates cap structures for the 
viral mRNAs (from the hosts mRNA)  
PB1 
Basic Polymerase Protein 1 
Part of the RNA polymerase complex. Transcriptase. Elongation of RNA 
 2 PB1-F2 
Basic Polymerase Protein 1-Frame 2 
Alternative reading frame of PB1. Regulation of the immune response. Mitochondrial 
protein.  
3 PA Acidic Polymerase Protein 
Part of the RNA polymerase complex. Transcriptase. Exact function poorly 
understood.  
4 HA Haemagglutinin 
Surface protein that binds to sialic acid on the host cell surface. Fusion of the viral and 
cellular membrane. 
5 NP Nucleoprotein 
Encapsidates the vRNA and the polymerases to RNP. Transport of vRNA 
6 NA Neuraminidase 
Surface protein. Release of new viral particles from the host cell.  
M1 
Matrix Protein 1 
Form a layer between the viral membrane (host membrane) and the RNP. Essential for 
nuclear export of RNP. 7 M2  
Matrix protein 2 
Membrane protein that is an ion channel, and responsible for pH regulation. 
NS1 
Non-structural Protein 1 
Regulatory protein on the cellular and viral protein expression. Not essential? Inducer 
of proinflammatory cytokines in human macrophages. The only non-structural protein?
8 NS2 (NEP) 
Non-structural Protein 2 
(Nuclear Export Protein) 
Interacts with the M1-protein in the export of RNP. Low amounts in the virus.   
 
Table 2: Influenza A genome segments sorted after their size and an overview of the 
function of their products.  
1.2.3 Replication 
In humans, the influenza virus primarily infects the epithelial cells of the airways, 
where the HA binds to sialic acid residues on the epithelial cells. This binding results 
in endocytosis, and the formation of an endosome in the cell cytoplasm. The low pH 
inside the endosome triggers the fusion of the endosome membrane and the virus 
membrane, and results in an uncoating of the virus. The M2 proton channel in the 
virus facilitates an acidification of the interior of the virus, weakening the association 
of the M1 protein layer and resulting in release of the viral genetic material (RNP) 
into the cytoplasm of the infected cell. The RNP complexes are then transported into 
the nucleus of the infected cell, where the viral transcriptases PB1, PB2 and PA 
transcribes the viral RNA into messenger RNA for the synthesis of viral proteins. The 
viral RNA itself is also copied to form new RNPs for new viruses. The viral proteins 
HA, NA and M2 are transported to the cell membrane, where the M1 protein coats 
the inner part of the cell membrane, and then the new RNPs attach to the M1 and the 
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influenza particles bud through the membrane. This process is summarised in the 
figure 2. After the epithelial cell has produced thousands of new viruses, the cell dies, 
and this results in a desquamation of the epithelium. (103)   
 
 
Figure 2. Illustration of the replication of the influenza virus. (Illustration courtesy of Dr A. 
J. Cann, University of Leicester, UK.) 
1.3 Antigenic Drift and Shift 
Both the A and B viruses are constantly mutating due to hosts selection pressure. 
These mutations can result in antigenic changes in the important surface 
glycoproteins HA and NA, but also other antigenic viral proteins (73) that are 
important for the virus to escape the hosts’ earlier acquired immunity. Antibodies to 
HA neutralise the virus, and are therefore important in the hosts’ ability to prevent 
infection and clearance of the virus. Accumulation of minor changes in the 
antigenicity causes antigenic drift. This means that the antigenic specificity of the 
antibodies produced are reduced, but not absent. If a new subtype of influenza virus 
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HA or NA emerges this is often due to genetic reassortment with an avian virus. If 
the HA (and/or NA) are exchanged with a human influenza virus, the acquired 
immunity to the surface glycoproteins is absent and this change is called an antigenic 
shift. Only the A virus has reportedly been able to genetically reassort (shift). If an 
influenza A virus reassorts either or both of the HA or NA segments, this may be the 
initiation of a new pandemic strain to which the population does not have any 
immunologic memory. 
1.3.1 Antigenic Drift 
The replication of the influenza A virus is an error-prone process. The virus has no 
system for proof reading of the transcription of its genes. In laboratory experiments 
the estimated influenza virus mutation rate is on average 1,5x10-5 mutations per 
nucleotide per infectious cycle (70;87). There are a total of approximately 14.000 
nucleotides in the influenza genome, giving an average of one point mutation in 
every 5th virus. Most mutations are silent, some may result in developing non-
functional viruses (negative mutations), but a few may alter the immunological 
properties to more favourable regarding survival of the virus. By this mechanism the 
viruses adapt to the immunologic pressure of the host. This is the reason for the 
annual influenza outbreaks, and why the composition of the influenza vaccine has to 
be evaluated and updated each year. 
The influenza B (and C) viruses also drift, but at a much slower rate.   
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Figure 3. Antigenic drift. Illustration courtesy of ”National Institute of Allergy and 
Infectious Diseases” (93) 
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1.3.2 Antigenic Shift 
The natural reservoir for influenza A virus is aquatic birds (with a stronghold in 
China and South-East Asia), where all the 16 different HA and 9 different NA are 
found. The avian and the human virus HA have slightly different affinity to sialic 
acid residues on the epithelial cell membrane. In humans the main target is the 
respiratory epithelium in the upper and lower airways. The background for the low 
infectivity of avian influenza in humans is the requirement for a different receptor 
configuration on the host cells. The human influenza HA preferentially binds to sialic 
acid with galactose in a α2,6 configuration, while the avian influenza virus prefers a 
α2,3 configuration. Pigs has both the α2,3 and the α2,6 configuration of sialic acid in 
the upper respiratory tract mucosa, and can therefore be infected with both human 
and avian influenza viruses. If a pig cell is simultaneously infected with a human and 
an avian influenza virus, it can act as a mixing vessel for the two viruses, and this can 
result in a reassorted humanized influenza virus with new avian genes (Fig 4). This 
virus can infect humans that have no pre-existing immunity (antibodies) against the 
new virus and this can then result in a pandemic. 
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Figure 4. Antigenic shift. Illustration courtesy of ”National Institute of Allergy and 
Infectious Diseases” (94) 
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1.4 Upper Airway Mucosal Immunology 
The defence against pathogens can be divided into two different systems, the innate 
(non-specific) and the adaptive (specific) immune system. It can also be viewed as 
lines of defence, where the first line of defence is the “peaceful” existence of our 
microbes, the so-called normal flora. Our body is inhabited by microbes in a number 
which is a tenfold higher than the number of human cells (79). The normal flora 
prevents new colonisation by potentially pathogen microbes. The second line of 
defence is the mechanical barrier of the epithelium, together with the mucus, the 
olfactory system and mucociliary function. The third line of defence represents the 
non-specific cell response from epithelial cells, phagocytic cells (APC’s) like 
macrophages and dendritic cells, and natural killer cells. The forth and last line of 
defence, is the specific response to antigens by B and T lymphocytes and their 
collaborating cells, cytokines and other signalling factors and pathways.   
Much of the immunological knowledge related to influenza is obtained from research 
in small animals. The mouse model is very popular, but influenza virus infections 
does not naturally infect mice (29). The anatomical distribution of the local lymphoid 
structures are also different in mice and men (88). Therefore, caution should be 
exercised in the translation of results from animal studies into human use (45;71).   
1.4.1 The nose and nasal mucosa 
The nose is the entrance to the respiratory tract, and is therefore vulnerable to 
airborne infectious agents. Influenza virus can spread by droplets and aerosols in the 
air produced by infected hosts as they sneeze and cough. The nasal mucosa is 
normally the site where respiratory viruses meet the immune system of the host and is 
a potential site of infection.  
In human nose breathers about 20,000 litres of air passes through the approximately 
10cm (anterior-posterior-direction) of the nasal mucosa (or 150cm²) every day. The 
air is filtered for all particles larger than 2-5μm, heated up to 32 degrees Celsius and 
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moisturised to approximately 98% humidity. The nasal mucosa has the ability to 
rapidly respond to different stimuli by increasing the blood flow, mucosal thickness 
and secretory capability.  
The respiratory epithelium is ciliated with tight junctions, and this represents a 
mechanical barrier to inhaled agents. There is also a high turnover of epithelial cells 
in the mucosa. The mucus covering the epithelium contains a range of different 
substances, and both specific (SIgA) and non-specific anti-microbial agents protect 
the epithelium from infection. If the influenza virus reaches the cell surface it binds to 
sialic acid and can then infect the epithelial cell and replicate (30). 
The role of antibody secreting cells (ASC) in long-term immunity of the mucosa, 
their life span and migration is not clearly understood, although it is more than 60 
years since they were first discovered (47). In mice infected intranasally with 
influenza virus, antigen specific ASC’s are up-regulated in the nasopharynx-
associated lymphoid tissue that line the nasal passage – the so called diffuse NALT 
(D-NALT), and has a lifelong effect (56). These murine ASC’s mainly produce IgA. 
Mice immunised with respiratory syncytial virus (RSV) intranasally maintains a 
RSV-specific plasma cell population in the NALT, which induces protective 
immunity against subsequent RSV exposure. This nasal immunisation is even “better 
than nature” because infection with RSV only gives short-lived up-regulation of 
RSV-specific ASC in D-NALT and does not protect from later infection (36;82).  
1.4.2 Mucosa associated lymphoid tissue/Tonsils/Waldeyer’s ring 
Mucosa associated lymphoid tissue (MALT) is a secondary lymphoid organ that 
consists of aggregates of lymphoid cells organised beneath the epithelium of the 
airway and digestive tracts. The organised lymphoid structures in the upper 
aerodigestive tract (Fig.5) are anatomically located in and around the pharynx. They 
contain the palatine (Fig.6), the nasopharyngeal, the lingual and the tubal tonsils that 
together with minor lymphoid aggregates found spread in the lateral and posterior 
pharyngeal wall and called the Waldeyer’s ring (after the German anatomist Wilhelm 
 28 
von Waldeyer-Hartz (1836-1921)). These secondary lymphoid structures are built up 
like a lymph node with B- and T-cells organised into follicles. Tonsils are important 
structures in the mucosal immune system as stations for immunomodulation and 
homing of lymphoid cells, and we have counterparts in the respiratory and 
gastrointestinal tracts (Example: Peyer’s patches in the small intestine and the 
appendix) (9;71).   
 
Figure 5. Lateral view of the upper respiratory tract. From Gray’s anatomy. 
 
Removing the “tonsils” is a relatively common surgical procedure. The indications 
for these operations are typically hypertrophy of the tonsils causing respiratory 
problems such as obstructive sleep apnoea (OSA) and serous otitis media (“Glue 
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ear”) or recurrent infection e.g. chronic or recurrent tonsillitis (69;98). Surgical 
removal of the palatine tonsils (tonsillectomy) and the nasopharyngeal tonsil 
(adenoidectomy) are probably the most common operations performed on children 
and young adults, but is still somewhat controversial (21). There are studies showing 
effectiveness of tonsillectomy in children with major recurrent tonsillitis problems 
(69). In children with fewer upper respiratory tract infections than the indications 
described by Paradise et al. (69) there is no significant effect of adenotonsillectomy 
(57;98). In adults there are only limited data on the long term effect of tonsillectomy, 
and according to the latest Cochrane Library Review from 2000 (21) there is no 
evidence for the effectiveness. Some recent studies show a significant effect also in 
the adult population (3;50). Adenoidectomies and tonsillectomies are very common 
operations in Norway and world-wide, and the satisfaction rate of the patients and 
their parents is high (50;62;86;104). The standard indications for tonsillectomy in 
Norway are described in Guidelines for ENT-diseases: Norwegian Society of 
Otorhinolaryngology Head & Neck Surgery, 1998 (60).  
 
Figure 6. Photo of the fauces with the pared palatine tonsils. From Wikipedia. 
The question of how adenoidectomy and tonsillectomy affects the immune system 
and particularly the upper airway mucosa immunology is widely debated. Since these 
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operations are some of the most common operations in the world, it may seem that 
removal of a part of the MALT in the Waldeyer’s Ring does not seem to result in a 
major immunological disadvantage. This may be due to other parts of the local 
MALT replacing the function of the removed tissue. The tonsils are important sites of 
B-cell proliferation and differentiation, and act as both inductor and effector sites (9). 
Ogra observed in 1971 that the level of IgA antibodies in the nasopharyngeal fluid 
was reduced after adenotonsillectomy (66), and Östergaard found in 1977 low levels 
of IgA after tonsillectomy in both serum and saliva two years after the operation (68). 
Others have shown that despite changes in the immune system, there is no increase in 
immunological or infectious diseases (11;53;78). However  in recent years a 
conservative attitude towards adenotonsillectomy is recommended and practised (12). 
Since the tonsils are the only easy accessible human lymphoid organs (65), and 
adenoidectomy and or tonsillectomy is a common procedure, there are numerous 
studies on human hypertrophied and recurrent infected tonsils and little on normal 
tonsils (Reviewed in references (12;80).  
1.5 The immune response to influenza  
1.5.1 The immune response to influenza infection 
The fact that our body is constantly challenged by a vast number of microorganisms, 
and we seldom get infected, demonstrates the power and potency of the innate 
immune system. The innate immune system is fast acting, detecting and destroying 
influenza viruses immediately or within a short period of time (91). One component 
of the innate system is the mechanical barrier of the respiratory epithelium, which has 
a high turnover of cells and is ciliated. The cilia are the mucosal motor that moves the 
mucus blanket that can harbour microbes to the nasopharynx for expectoration or 
swallowing. The mucus itself contains a variety of potent antimicrobial factors like 
lysozyme, lactoferrin, peroxidases (76), secretory antibodies like SIgA (also IgG and 
IgM), that can neutralise the influenza virus, and other inhibitory factors that can 
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reduce the viruses ability to infect the epithelium. The cellular part of the innate 
immune system are the phagocytes, like macrophages, dendritic cells and furthermore 
neutrophils, eosinophils and mast cells. They can eliminate influenza virus and 
produce cytokines that inhibit the virus replication, cause fever and recruit natural 
killer (NK)-cells that limit viral spread by killing infected cells. The complement 
system may also play a role in the innate immune response to influenza virus 
infections (91).  
If the virus escapes the early innate defence mechanisms, it will be recognised by the 
adaptive immune system. The phagocytic activities of macrophages and dendritic 
cells are essential in removing foreign antigen/microbes and for presenting antigen in 
the induction of the antigen specific response of the T- and B-lymphocytes (Fig.7). 
The full effect of the effector function of the adaptive immune response is revealed 
after some days (4-7days (30)), and starts with the inflammatory response that allows 
the antigen presenting cells better access to viral antigen. The APCs (mainly dendritic 
cells) then migrate to lymphoid tissue (e.g. MALT) where they present surface bound 
antigens to T-cells, and start an antigen specific clonal expansion of effector 
lymphocytes, which migrate back to the site of infection. This adaptive immune 
response can be divided into a cell mediated response conducted by the T-cells, 
mainly CD4+ and CD8+ T-cells, and a humoral response involving B-cells and 
antibody production. A highly complex signalling of different cytokines regulates 
and co-ordinates this immune response. In influenza virus infection there are a 
number of different cytokines that act pro-inflammatory (IL-1β, IL6, IL18, IFN-α/β, 
TNF-α) and antivirally (IFN-α/β), and are also responsible for many of the symptoms 
that occur during infection (83). During experimental influenza infection in humans 
there was an early peak in nasal lavage fluid (mucus) of IL6 and IFN-α, which 
correlated directly to symptoms and viral load (46).  
The B-cells that migrate to the lamina propria of the mucosa at the site of infection 
produce mainly the dimeric IgA, which is actively transported through the epithelial 
cells. Since IgA does not activate the complement system and therefore is considered 
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to be non-inflammatory, it can bind to and neutralize virus both in the mucus, inside 
the epithelial cells and in the lamina propria without causing tissue damage (13). The 
SIgA level in the mucus correlates inversely with the virus titre (91). There is also a 
lower concentration of both IgM and IgG in the mucosa. IgM can also be transported 
through the epithelium to the mucosal surface if it contains the j-chain (bound to 
secretory component), but IgG can only leak (transudate) through the mucosa or via 
minute injuries in the epithelium. IgG is the dominant antibody in serum, and seems 
to have an important role in the defence against influenza viruses in the lower airways 
(lungs) (13).  
The activation of CD8+ T-cells into cytotoxic T lymphocytes (CTLs), mediate killing 
of infected cells that presents foreign viral antigens on MHC class I (109).    
Recovery from influenza infection is a 2-stage process. On days 5-7 T-cell dependent 
killing of infected cells is highly active, and there is  subsequent elimination of the 
virus by local/mucosal antibodies (SIgA) (91). 
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Figure 7. Overview of the defence mechanisms induced by influenza virus infection. From 
(91). Reproduced with permission. (Illustration courtesy to Japanese Journal of Infectious 
Diseases and Shin-ichi Tamura, PhD, Tokyo, JAPAN.) 
 
1.5.2 The immune response to influenza vaccination 
The efficacy of influenza vaccination varies by multiple parameters, e.g. vaccine 
type, vaccination route, immunologic status, age and match of vaccine to the 
circulating strains (40). Most adults have experienced several influenza infections 
during life and the immune system have memory to the subtypes of the virus 
circulating. Therefore one dose of the commonly used inactivated influenza vaccine 
will normally provide in protective levels of antibodies 60-90% of cases (Reviewed 
in (25). Young children, which may be immunologically naïve to influenza, may need 
more than one dose to get properly immunized. The different vaccines on the market 
have different immunogenic properties, and can also vary from year to year.  
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The vaccines with killed virus, given as an injection subcutaneously or 
intramuscularly, will in primed individuals provide a rapid systemic humoral immune 
response in the blood, and a weaker humoral local response in tonsils and oral fluid 
(Fig. 8). In serum the antibody response is dominated by influenza specific IgG-
antibodies, and lower amounts of IgM and IgA antibodies towards the surface 
antigens HA and NA (32). Accordingly, the ASCs found in blood are also mainly 
IgG positive, with minor IgA and IgM positive cells (108). In saliva the main 
antibody response is of SIgA1 type (18). In influenza naïve children IgM dominates 
the systemic immune response, and there is very low concentration of SIgA induced 
in saliva (32). 
LAIV vaccines given nasally induces a stronger local immune response, but a weaker 
systemic response (25). However, LAIV vaccines have the advantage that they also 
stimulate a cellular immune response, inducing influenza specific CD8+ T memory 
cells. A newly published study in mice showed that the combination of one intranasal 
followed by one intramuscular immunization gave the best immune response, 
compared to 2 intramuscular, 2 intranasal or one intramuscular followed by 1 
intranasal vaccine (97).  
The proposal of an universal influenza vaccine targeting more stabile epitopes like 
the M2 proton channel may have several advantages (28). This could allow influenza 
vaccination to be more like the vaccination programs for other pathogens (e.g. 
rubella, polio etc), with a few vaccinations in a lifetime. A recent interesting study in 
mice shows that pulmonary vaccination is a new potential route of influenza 
vaccination, and seems superior over the intranasal, intramuscular and oral route in 
that it elicits a strong immune response both locally and systemically (58). 
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Figure 8. The figure shows an outline of some of the main immunological events (and 
kinetics) after an influenza vaccination, both systemically and locally (17;26). Most adult 
subjects have detectable serum antibodies (AB) prior to immunization. This is seen in many 
of our studies, e.g. [Paper I, II]. Immediately after vaccination the serum levels drops, which 
may be due to quick complexing of anti-influenza AB with influenza antigen. The serum AB 
rises quickly again and are significantly higher at 4-5days post vaccination (PV). The peak 
in serum AB levels occurs after 8-9 days PV, and then it falls slowly, but is still relatively 
high after 3-4 weeks PV. The number of influenza specific antibody secreting cells (ASC) in 
blood and tonsils is very low before vaccination. These cells proliferate quickly and are 
significantly higher in number at 4-5 days PV, with a peak after 7 days, and a rapid drop to 
basal levels after 2 weeks. The proportion of influenza specific ASC is much higher in blood 
than in tonsils, but may not represent a higher total number. The salivary AB against 
influenza follows the tonsillar ASC, but since we only detects AB produced and secreted in a 
limited time period, the salivary AB levels drops together with the local influenza specific 
ASC levels.  
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1.6 Influenza the disease 
There are a large number of viruses which cause respiratory tract disease in humans. 
The symptoms vary from very mild clinical and sub-clinical, to the more severe 
disease caused by the influenza A virus.   
The influenza season in Norway usually starts in November-December and ends in 
February-March, although there is a great annual variation in this pattern (63). 
For most people, a true influenza virus infection is a self-limiting disease that has the 
typical pattern of fever, headache, myalgia and cough. The clinical picture can be 
quite different for individuals with chronic diseases or immune dysfunction.   
1.6.1 Pathogenesis 
For many viruses asymptomatic or sub-clinical infection is most common, but for 
influenza virus infection most infected individuals also become ill (96). In general the 
pathogenesis of influenza depends on many interacting factors of the host and of the 
viruses. The most important host factors in humans that determine the pathogenicity 
and severity of the clinical picture are age and co-morbidities, e.g. 
immunocompromised individuals, elderly people (especially those living in close 
contact in nursing homes), young children with a naïve immune system and people 
with serious chronic diseases (e.g. heart, lung and metabolic diseases). The different 
subtypes of influenza A virus are also associated with different levels of morbidity 
and mortality, e.g. the H3N2 subtype is associated with higher mortality than the 
H1N1 (101).  
The transmission of influenza from person to person is primarily by aerosols and 
droplets, but direct and indirect contact is also a possible route of transmission. Data 
suggest that the smaller droplets (1-4μm in diameter), mainly produced by sneezing, 
enter deeper in the airways and require less virus particles to be infective than larger 
droplets that are deposited in the nasal cavity (5;14). 
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The incubation period varies from 1-4 days and infected adults normally shed virus 
for 3-5 days. Children and immunocompromised persons can shed virus for a much 
longer period (14). 
In humans, influenza virus infection mainly targets the epithelial cells of the upper 
respiratory tract, where it starts replication and causing tissue destruction. The 
disruption of the epithelial cell barrier and the additional local inflammatory response 
leads to the common symptoms of influenza: coughing, sneezing, sore throat, runny 
and blocked nose. The systemic symptoms of influenza are associated with cytokines 
produced in the inflammatory process. Many of these cytokines, such as IL-1, IL-6 
and TNF-α, are endogenous pyrogens. When they reach the hypothalamus via the 
bloodstream, they stimulate prostaglandin E2 production, inducing symptoms like 
fever, sleepiness, anorexia, myalgia and headache (19). The infection itself normally 
does not spread to other tissue or organs outside the respiratory mucosa in humans. 
1.6.2 Clinical manifestations 
Influenza infection can be either asymptomatic or symptomatic. Many people show 
increased antibody-titres for specific influenza viruses without knowing that they 
have been infected. According to the WHO, the annual influenza epidemics affect 
approximately 5-15% of the population, which results in a significant increase in 
morbidity and mortality and an associated socio-economic burden (106). In the 
United States, the influenza epidemics typically occur during the winter months and 
have been associated with an average of approximately 36,000 deaths per year during 
1990—1999 (95), mainly in the elderly population. A similar trend is also observed 
in Norway. The typical influenza illness is, in otherwise healthy individuals, a febrile 
infection lasting for approximately a week with typical symptoms of fever, cough, 
nasal congestion, headache and myalgia (61). Uncomplicated influenza is a self-
limiting disease that may need to be treated with bed rest for some days, absence 
from work and symptomatic treatment with analgesics and astringent nose drops. 
Small children which are immunological naïve to the influenza virus, patients with 
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chronic lung, heart or immune disease and elderly people are considered the risk 
groups for complicated influenza infection. In these groups the infection may be more 
serious and widespread and the mortality rate increase during an influenza epidemic 
(42).  
Influenza associated pneumonia, and secondary bacterial pneumonia are among the 
most common complications. Pneumonia with Staphylococcus aureus is linked to 
serious disease and high mortality (101). Other respiratory complications like acute 
sub-glottic laryngitis (pseudo-croup), otitis media and bronchitis are common in 
children and exacerbation of known respiratory diseases like asthma, cystic fibrosis 
and chronic obstructive pulmonary disease are also common. Other major 
complications are seldom present, but myo- and pericarditis, heart arrhythmias, 
encephalitis, Guillain-Barré-syndrom, myositis and rhabdomyolysis and Reye’s 
syndrome have been described (63).    
1.6.3 Diagnosis of influenza 
The diagnosis of influenza is normally based on patients’ history and clinical 
presentation and findings. Normally doctors do not take an aspirate from the upper 
airway (“virus sample”) in order to diagnose influenza virus infections, if it is known 
that influenza is circulating in the community. Studies have shown that during an 
influenza epidemic the clinical diagnosis alone was correct in about 3 out of 4 
patients (111). The symptoms that were the best predictors for influenza infection 
were acute onset of cough and fever, with a positive predictive value of 79% (61). A 
recent study shows that depending on the setting the relationship between the clinical 
diagnosis and the laboratory verification of the virus can be very low (49). There are 
rapid tests for detection of influenza antigen available, but their sensitivity is 
generally low. However, these tests can be useful in some settings (75). The single 
most important factor in making the correct diagnosis is to know whether influenza 
virus is circulating in the community or not (111). 
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In Norway and other countries there are multiple general practitioners that act as 
watchtowers in the surveillance of influenza. At present there are 201 offices and 
emergency units in Norway that report all cases of influenza-like illness each week 
during the autumn, winter and spring season in the typical influenza period in the 
northern hemisphere. These data are then made commonly available through weekly 
published reports (MSIS). This surveillance system contributes to the knowledge of 
the influenza activity and severity.  
In addition, 70 general practitioners submit nasopharyngeal samples from patients for 
influenza testing to The Norwegian Institute of Public Health (Folkehelseinstituttet). 
Together with reports from the microbiological laboratories in Norway this gives 
important information on the viruses circulating in the community. This surveillance 
is done in collaboration with the WHO and the European Influenza Surveillance 
Scheme (EISS).  
1.6.4 Social and economic impact of influenza 
The economic considerations of diseases and their treatment are becoming more 
important in the Norwegian Health Care system, similarly to the situation in the USA. 
The cost-efficacy or cost-benefit of treatment and cost of illness are important 
parameters for the health-care providers in their decision of where to spend the 
money. As in all fields of medicine there are difficult moral and ethical questions 
raised, and it is not unproblematic to put a price tag on life, suffering and death. 
An estimate from the WHO is that there are annually 3-5 million cases of severe 
influenza illness, and 250,000-500,000 die from it in the industrialised world. This of 
course varies from year to year, but data from USA over the last decade reveals an 
average annual mortality rate of 120/million inhabitants and hospitalisation rates of 
670/million. The majority of patients hospitalised or dying from influenza are elderly 
(102).   
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The cost of the annual influenza epidemics is difficult to calculate, and depends upon 
multiple parameters. A new study from Centers for Disease Control and Prevention  
has systematically estimated the costs of annual influenza in the USA to $87.1 
billion, where medical costs alone counted for  $10.4 billion (59). The majority of the 
costs arise from work absenteeism and lives lost.  
Several studies have shown that vaccination is not only cost-effective but even cost-
saving, also in the non-risk groups (1;89).  
1.7 Prophylaxis and Treatment 
The cornerstone of influenza prophylaxis is vaccination, especially for risk groups. 
The WHO has set the criteria for the risk groups which should be implemented in the 
influenza vaccination program.  
Treatment of an influenza infection depends on the severity of infection and of the 
related complications. Generally influenza is a self-limiting disease that with or 
without the help from the doctors is symptomatically treated with bed-rest, analgesics 
and astringent nose-spray/drops.  Other general recommendations during the 
influenza season are good hand hygiene, and avoid coughing and sneezing on others. 
Those who are ill should stay at home and rest.  
Complications of influenza infection are relatively common, especially in children 
and elderly patients and patients with chronic diseases. 
The use and development of anti-influenza drugs are still in its infancy. Although 
some of them are effective short term, they do not encompass the cost-effectiveness 
of influenza vaccination (2;7;63).  
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1.7.1 Vaccination 
Influenza vaccination is today the primary method for preventing influenza and 
severe complications related to the disease. Numerous reports and studies have shown 
the effect of vaccination on morbidity and mortality (52;74;85) 
Beneficial cost-efficacy relationships have been shown for influenza vaccination. 
Recently (77), the need of influenza vaccination in the at risk-group of patients in the 
25 countries in the European Union (not including associated members such as 
Norway) was estimated. The authors estimated that 49.1% of the total population 
(223.4 million people) should be vaccinated annually. They postulated that if 100% 
of persons in the at risk-groups received influenza vaccine, this would reduce the 
number of influenza cases by 7.22 million, 1.92 million reduced primary care visits, 
796.000 hospital admissions and 68.500 fewer influenza related deaths. Not only 
would the morbidity and mortality be reduced, but the costs of this vaccination-
program would be saved by reduced primary care visits and hospitalisations (77).  
Influenza vaccine development started shortly after the influenza virus was 
discovered. Inactivated influenza vaccines were introduced in the 1940s, and this is 
still the most common formulation of influenza vaccine. The virus strains of the 
vaccines are updated twice a year by the WHO’s Global Influenza Surveillance 
Network, for the northern and southern hemisphere. The vaccines are made by 
propagating the influenza viruses in embryonated hen’s eggs. The annual influenza 
vaccines contain H1N1, H3N2 and B virus antigens.   
There are several types of influenza vaccines, and the main variants are the live 
attenuated and the killed virus vaccines. The killed virus vaccines may be whole 
viruses (whole-virus vaccine), disrupted viruses (split-virus vaccine) or the purified 
surface antigens (sub-unit vaccines). The killed virus vaccines are mainly given as an 
injection subcutaneously or intramuscularly. Live attenuated virus vaccines are 
administered as a nasal spray and this vaccine is for the time being not available in 
Europe. In Norway, only split and sub-unit vaccines for influenza immunization are 
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available. Live attenuated influenza vaccines (LAIV) have for many years been used 
by the Russians and in the latter years also in the USA (“Flumist®”).  
The WHO has set a goal of 75% vaccine coverage in the influenza at risk group 
within 2010. Norway has one of the lowest vaccination rates of the at risk groups, 
with approximately 45% of the individuals vaccinated (7). In a large study of the 
macroepidemiology of influenza vaccination in 56 countries, Norway was in 30th 
place, among countries like Slovenia and Uruguay, and far behind the leading 
countries Canada, Korea and USA (92). The reason for this low vaccine coverage in 
the at risk groups in Norway may be multifactorial, but the main reason is probably 
that these people do not see the need for vaccination and that influenza is not seen as 
a serious illness (7). Lack of information and recommendation from doctors may also 
be a reason for this. In this context the vaccination rate among health-care workers is 
very low, despite the recommendations from WHO and studies showing significant 
reduction in mortality among patients when the staff are vaccinated (Reviewed in 
reference (20). The attitude among health-care workers towards influenza-vaccination 
can also be a reason for the general low influenza vaccine coverage in Norway (7).  
Side reactions after influenza vaccination are commonly minor, e.g. tenderness, 
oedema and erythema at the injection site. Some people experience a minor influenza 
like reaction, but serious side effects of vaccination are extremely rare. Among 3.5 
million influenza immunizations in Norway, 4 people had to be hospitalised. One 
person died, without a clear relationship to the components of the vaccine (7).  
Children are more prone to influenza infection, while serious illness and deaths are 
higher among persons aged >65 years, children aged <2 years, and individuals of any 
age who have medical conditions that place them at increased risk for complications 
from influenza. 
In Norway the following groups are considered at high risk (about 900,000 persons) 
and are recommended for annual influenza vaccination (The Norwegian Institute of 
Public Health):  
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1. Persons that are 65 years or older 
2. Adults and children with serious airway conditions, especially persons with 
decreased lung capacity 
3. Adults and children with chronic heart and blood vessel diseases, especially 
persons with serious heart failure, low minute volume or pulmonary 
hypertension  
4. Adults and children with decreased resistance against infections  
5. Adults and children with diabetes mellitus (both type 1 and type 2)  
6. Adults and children with chronic renal failure  
7. Persons living in nursing homes for the elderly  
The latest recommendations of the Advisory Committee on Immunization Practices 
(ACIP), CDC, USA from 2007 now promotes a more active vaccination program 
including more conditions in the at risk group (38). The most important differences 
are that the CDC recommendations include young children down to 6 months of age, 
persons over 50, pregnant women and health care workers.  
1.7.2 Antiviral drugs 
Antiviral drugs against influenza have been on the market for some time, but their use 
is limited, and they are not a substitute for influenza vaccination. There are two main 
indications for the use of antiviral drugs against influenza; in prophylaxis and 
treatment of influenza. When treating influenza with antiviral drugs, the medication 
should be started within 48 hours of the onset of symptoms, and only if influenza 
virus is verified (by rapid tests) or undoubtedly the reason for the symptoms. The 
duration of the influenza can be shortened by 1-4 days of treatment. Prophylactic use 
could be indicated to prevent influenza in a community or closed facility like a 
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nursing home, or if an at risk person is allergic to eggs, and therefore can not receive 
the vaccine.  
There are two principle types of anti-influenza drugs available. The M2-channel 
inhibitors, amantadine and rimantadine, are only effective against influenza A. The 
use of the M2-channel-blockers is not approved in Norway, and their use is 
associated with substantial side-effects. The other group of antiviral drugs against 
influenza is the neuraminidase inhibitors, zanamivir (Relenza®) and oseltamivir 
(Tamiflu®). They are effective against both influenza A and B viruses, and are both 
registered for use in Norway (2).  
According to the guidelines from the UK National Institute for Clinical Excellence in 
2003 (64), the only people that should be treated with antiviral drugs, are patients in 
the at risk groups, and they do not recommend the use of amantadine (and 
rimantadine, which is not available in the UK). 
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2. The Study 
2.1 Aims of the study 
The main objective of this study was to examine the local and the systemic immune 
response after parenterally administered inactivated influenza vaccine in adults. Our 
focus was on the immune response in the palatine tonsils, nasal mucosa, saliva and 
peripheral blood/serum. This work is a follow up of studies performed by the 
influenza research group in Bergen (15;31).     
The specific aims of the four publications were:  
1: To determine the basal level of influenza-specific antibody secreting cells (ASC) in 
the blood (systemic compartment), tonsils (local lymphoid organ) and nasal tissue 
(local mucosa). 
2: To evaluate the effect of parenteral influenza vaccination on the number of 
influenza virus specific ASCs locally in the tonsils and nasal mucosa.  
3:  To investigate the effect of influenza vaccination on the distribution of lymphoid 
cells in the palatine tonsils. Since parenteral vaccination induces humoral immune 
responses in the tonsils, we wanted to examine if vaccination has an impact on other 
immune competent cells in the tonsils.  
4: To study the levels of cytokines and chemokines produced locally and systemically 
after influenza vaccination of patients undergoing tonsillectomy.  
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2.2 Materials and Methods 
2.2.1 Patients 
This study is based on 4 clinical trials, summarised in table 3. All our patients were 
recruited from the dept. of ORL-HNS at Haukeland University Hospital. The patients 
were referred to our department by an ENT-doctor who had judged them to have 
indications for a tonsillectomy because of recurrent tonsillitis and/or hypertrophic 
tonsils. From this cohort we included suitable patients who conferred to our inclusion 
criteria. Our patients were with exception of their tonsillar problems healthy, not on 
regular medication (except hormonal contraception) and did not have allergic disease. 
We have obtained all appropriate approvals for our studies and the regional ethical 
committee approved our studies. The patients were sent written information and 
asked to take part in our study, and they were examined 1-2 weeks before the 
operation. Those who signed the informed consent form were then included in the 
study. Saliva and blood samples were collected from all patients at the time of 
inclusion. The patients in trials 2-4 were then sorted into a control and a vaccinated 
group. The patients included in the vaccination group(s) were subcutaneously 
vaccinated with a standard dose of the seasonal influenza split virus vaccine 
according to the manufacturers’ instruction. No side reactions to the vaccination were 
reported or observed, apart from a few cases of minor local inflammation at the 
injection point.  
In the first and second trials we collected a unilateral biopsy from the mid part of the 
inferior turbinate in the nose. This was done under general anaesthesia before 
tonsillectomy, with local anaesthesia (Tetracaine with Adrenaline) at the site of the 
biopsy.  
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Table 3. Summary of patient groups studied. 
 
 
 
 
Trial 1 2 3 4 
Time of trial Spring 2000 Autumn 2000 Autumn 2002 Autumn 2004 
No. of subjects 19 23 33 25 
Sex M/F 9/10 11/12 9/24 12/13 
Age-range (years) 17-40 16-38 16-56 18-59 
Mean Age (years) 28 26 25 27 
No. of controls   9 5 
Vaccine strains None    
H1N1  A/New Caledonia/20/99 A/New Caledonia/20/99 A/New Caledonia/20/99 
H3N2  A/Panama/2007/99 A/Panama/2007/99 A/Wyoming/3/2003 
B  B/Yamanashi/166/98 B/Shangong/7/79 B/Jiangsu/10/2003 
Vaccine 
Manufacturer Fluarix® Fluarix® Fluarix® 
  GlaxoSmithKline® GlaxoSmithKline® GlaxoSmithKline® 
Samples Blood/Serum Blood/Serum Blood/Serum Blood/Serum 
 Oral fluid Oral fluid Oral fluid Oral fluid 
 Tonsils Tonsils Tonsils Tonsils 
 Nasal mucosa Nasal mucosa   
Papers I, II, III II, III IV IV 
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2.2.2 Laboratory tests 
We collected blood, saliva, tonsillar and nasal mucosal tissue from patients. In these 
studies we have used the following immunological methods to examine the immune 
response after vaccination: 
Enzyme-Linked ImmunoSorbent Assay (ELISA):   
We used the ELISA technique to analyse the level of influenza specific antibodies in 
the serum and saliva, before and after influenza vaccination.  
Enzyme-Linked ImmunoSPOT Assay (ELISPOT) 
The ELISPOT technique was used to enumerate the influenza specific antibody 
secreting cells (ASC) in lymphocytes from blood, nasal mucosal tissue and from 
tonsillar tissue. The results from peripheral blood lymphocytes were compared before 
and after vaccination. Since pre-vaccination samples from tonsils and nasal mucosa 
were not available, the levels of influenza specific ASC from post-vaccination 
samples were compared with data from non-vaccinated volunteers (control group). 
Haemagglutination Inhibition Assay (HAI) 
This is the “gold standard” method for measuring influenza specific antibodies in 
serum and is commonly used as a surrogate of protection. A serum HAI titre of 40 has 
been deemed to be protective against influenza virus infection (48).  
Immunohistological staining of cell surface markers 
Tonsils were cryopreserved and sectioned before immunohistological staining against 
14 different cell surface markers: CD4, CD8, CD19, CD20, CD45RA, CD45RO, 
Mac387, CD68, CD11b, CD11c, HLA-DR, E-cadherin (CD144), IL-3rα (CDw123), 
CD1a.  
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Fluorescent labelling of influenza specific antibody secreting cells 
Cryosectioned tonsillar tissue was stained with fluorescent tagged influenza antigen 
and counter stained. The sections were analysed using a fluorescence microscope and 
the influenza specific ASC counted (ASC/mm²). To our knowledge this is the first 
report of identifying single influenza specific ASC’s in tissue.  
Multiplex Bead Immuno Assay 
We have analysed the concentration of 25 cytokines and chemokines directly in the 
serum and saliva of both vaccinated and non-vaccinated patients using the multiplex 
bead immuno assay. A 10-plex cytokine assay was used to analyse cytokines in 
supernatants from lymphocyte stimulated in in vitro cultures. We used a Luminex 
100 instrument (Luminex Corporation) with STarStation software (Applied 
Cytometry Systems) to read and analyse the data. 
Quantitative PCR (QPCR) 
Cytokine gene expressions (10 of the most common cytokines) were measured on a 
7500 Real Time PCR system (Applied Biosystems) in lymphocytes from whole blood 
samples that were collected in PAXgene tubes (PreAnalytix GmbH) which freezes 
and preserves the mRNA expression levels.  
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2.3 Summary of Results  
2.3.1 Paper I 
High prevalence of influenza specific antibody secreting cells in nasal 
mucosa. 
This study was conducted to examine the basal level of influenza-specific antibody-
secreting cells (ASCs) in the local mucosa of the upper respiratory tract. Nineteen 
patients scheduled for tonsillectomy were enrolled in this study, and none of whom 
reported an influenza-like illness the previous winter. Tonsils, blood, saliva and a 
nasal biopsy were sampled from all patients. The Haemagglutination Inhibition Titre 
(HAI) showed that nine patients had HAI-titre above the level of detection (>10) for 
the H3N2 virus, and two had protective levels (≥40). For the two other viruses H1N1 
and B, none of the subjects had detectable HAI-titres. We also measured the 
concentration of total influenza specific antibodies in the serum and saliva by ELISA; 
which gave results comparable with the pre-vaccination concentrations observed in 
previous work. The level of influenza specific antibodies in oral fluid was low but 
detectable, and represents the production in a short time frame, whereas the serum 
levels represents an accumulated production over several days.  
Lymphocytes were isolated from blood, nasal mucosa and tonsillar tissue, and 
analysed by the ELISPOT method to enumerate the number of influenza specific 
antibody secreting cells (ASC) per million lymphocytes. In the biopsy from the nasal 
mucosa taken from the mid portion of the inferior turbinate (concha inferior) we 
found 10-100 times higher frequency of influenza specific ASC than in tonsils and 
blood. This reflects the basal influenza specific ASC frequency in the nasal mucosa, 
which represent an important first line of defence against influenza infection.  
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2.3.2 Paper II 
Parenteral vaccination against influenza does not induce a local antigen-
specific immune response in the nasal mucosa. 
This study was a natural follow up of the first paper, were we wanted to examine the 
immune response in the nasal mucosa and tonsils after parenteral influenza 
vaccination in 23 patients scheduled for tonsillectomy. All patients were healthy 
except for their hypertrophic tonsils or recurrent tonsillitis. In line with earlier results, 
we found that the influenza immunization induced a significant increase in influenza 
virus–specific serum and oral fluid antibodies at the time of the operation 7 days after 
vaccination. Lymphocytes were isolated from blood, tonsillar and nasal tissue. The 
numbers of influenza virus–specific antibody-secreting cells (ASCs) were measured 
by ELISPOT. In peripheral blood the number of influenza specific ASC increased 
significantly 1 week after vaccination. The numbers of ASCs in the tonsils and nasal 
mucosa were compared to data from paper I with the non-vaccinated volunteers, and 
for medical and ethical reasons pre-operative biopsies were not taken from the 
patients’ tonsils or nasal mucosa. We found that there was a significant increase in 
the number of influenza virus–specific ASCs in the tonsils in the vaccinated group. 
Surprisingly, in the nasal mucosa there was no difference in the number of ASCs 
between the vaccinated and the non-vaccinated patients.  
These findings indicate that the parenteral influenza vaccination elicits a systemic 
response. Since the nasal mucosa is an important tissue for the protection against 
influenza (and other) virus infections our findings may indicate that parenteral 
vaccination does not give the optimal immune stimulation and protection in the nasal 
mucosa. The increase in anti-influenza antibodies found in the saliva probably 
originates from other sources than the nasal mucosa.   
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2.3.3 Paper III 
Lymphocyte distribution in the tonsils prior to and after influenza vaccination. 
In the human pharynx the respiratory and gastrointestinal tract are joined. In this area 
we have the lymphoepithelial structures called the Waldeyer’s ring. There are 4 
tonsillar structures, namely the nasopharyngeal (epipharyngeal tonsil or “adenoids”), 
the tubal, the palatine and the lingual tonsils, together with smaller collections of 
lymphoid tissue, they form a complete ring structure. The tonsils are rich in 
lymphocytes and probably play an important role as a reservoir of memory and 
immune competent cells for the respiratory tract. The tonsils may also function as an 
inductor and effector site for immune responses against respiratory pathogens and 
foreign antigens. In this study, we examined if parenteral influenza vaccination had 
an impact on immunological cells in the palatine tonsils. We used histological tissue 
sections from the cryopreserved palatine tonsils from vaccinated and non-vaccinated 
patients (Trials 1 and 2) and stained these sections immunohistologically for 14 cell 
surface markers. The positively stained cells were counted by microscopy. We 
observed a significant decrease in CD4+ cells in the tonsils of vaccinated subjects. 
There was also a significant decrease in both naïve (CD45RA+) and memory 
(CD45RO+) T-cells after parenteral vaccination. The reason for this decrease is not 
known, but CD4+ T-cells, that are the major contributor to both CD45RA and 
CD45RO positive cells, may be recruited to the systemic compartment where they 
take part in the humoral immune response. The number of macrophages with the 
CD68 surface marker increased in numbers in vaccinated subjects, whereas the 
macrophages positive for mac387 did not change.  
We also stained histological tissue sections with influenza antigens labelled with a 
fluorescent tag to identify influenza specific antibody secreting cells (ASC) in tissue. 
To our knowledge this is the first report identifying single influenza specific ASC’s 
in human tissue. We found the influenza specific ASC spread throughout the tonsillar 
tissue, but mainly in the follicles, and the numbers of ASC significantly increased in 
the vaccinated patients. This finding is in line with our findings from paper II using a 
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different method, and their distribution in the tonsils probably shows that the 
influenza specific ASC’s have migrated/homed to the tonsils rather than been 
activated there.  
Our findings show that there are dynamic changes in the tonsils after parenteral 
influenza vaccination, and this indicates that the tonsils play an important role in 
immunity to respiratory pathogens.  
2.3.4 Paper IV 
The local and systemic cytokine and chemokine response after parenteral 
influenza vaccination. 
Cytokines are important mediators of immune responses, but they may also play a 
role in the symptoms and pathology of diseases. Since there is limited data on the 
cytokine response in man after influenza vaccination, we wanted to investigate the 
levels of cytokines produced locally and systemically after parenteral influenza 
vaccination. Our patients were as in our earlier trials scheduled for tonsillectomy, but 
otherwise healthy. Blood and saliva were sampled from all patients 1-2 weeks prior 
to, and at the time of operation. We also had a control group of non vaccinated 
patients. As a reference to earlier studies and to demonstrate that the vaccine 
stimulates the immune system, we measured the antibody response in serum and 
saliva by ELISA and the serum by HAI assay. The cytokine and chemokine 
concentrations were determined in both unstimulated samples (whole blood, serum 
and saliva) and in vitro influenza stimulated peripheral blood mononuclear cells 
(PBMC) and tonsillar lymphocyte (TMC) cultures. Influenza vaccination induced an 
immune response with protective levels of serum haemagglutination inhibition 
antibodies and a significant local antibody response in the saliva, as had been 
previously observed. There were no significant differences observed in the cytokine 
or chemokine levels between the vaccinated subjects and the non-vaccinated controls 
in either the serum or saliva. With Quantitative PCR we measured the gene 
expression levels of 10 common cytokines in PBMC of the vaccinated and non-
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vaccinated subjects. IL-5 and IL-10 were below the detection limit, and for the other 
cytokines there were no significant differences between the vaccinated and the non-
vaccinated patients. In supernatants from in vitro stimulated lymphocytes from 
peripheral blood and tonsils we found a significant increase in the concentrations of 
inflammatory cytokines in the vaccinated subjects. In PBMC after vaccination there 
were significant increases in the concentration of 8 of the 10 cytokines measured and 
in tonsillar lymphocytes we found significant increases in 6 of the 10 cytokines. The 
cytokine response in the vaccinated subjects revealed a mixture of type 1 and type 2, 
pro- and anti- inflammatory cytokines.  
Our data shows that it is difficult to detect changes in the cytokine profile one week 
after vaccination. In supernatants from in vitro stimulated lymphocytes in blood and 
tonsils there is an increase in different cytokines in the vaccinated subjects that 
reveals a heterogeneous cytokine profile. This data will provide useful baseline 
information for further research in the understanding of the immune response after 
influenza vaccination and also in trials of novel influenza vaccines.  
2.4 General Discussion 
The studies presented in this thesis were performed by collecting samples from 
patients undergoing tonsillectomy at the ENT department. The patients were both 
individuals vaccinated with the recommended trivalent influenza vaccine and non-
vaccinated controls. In this setting we were able to collect local lymphoid tissue 
(tonsils) as well as nasal mucosal biopsies, blood and saliva samples to examine the 
immune response induced after the influenza vaccination.  
The palatine tonsils are relatively large immunological tissues in the human body, 
extremely rich in immunocompetent cells. The main indications for performing 
tonsillectomy are recurrent or chronic inflammation of the tonsils and tonsillar 
hypertrophy. It can be discussed whether the tonsils which are removed are healthy or 
not, and therefore reflects the immunological process occurring in normal tonsils. 
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There are numerous immunological studies of tonsils, but almost all trials are 
conducted in patients with diseased tonsils and an indication for tonsillectomy. 
Studies have shown that there are microanatomical differences in normal and 
diseased tonsils (43) and also cellular differences in recurrent infected palatine tonsils 
versus idiopathically hypertrophied tonsils (67). Probably for ethical reasons, there 
are few human studies that have investigated differences in normal versus diseased 
tonsils regarding the specific immunological response to influenza disease or 
vaccination. In our studies we have compared the tissue samples from vaccinated and 
non vaccinated patients, and consequently changes observed are most likely due to 
the effect of vaccination.   
The nasal mucosa samples were also collected from the same patient group, but none 
of these patients were suffering from nasal diseases, so we consider these nasal 
mucosa biopsies to be from healthy mucosa.  
2.4.1 Systemic and local antibody response to influenza vaccine 
In earlier studies the antibody response to inactivated influenza immunization has 
been examined in detail (15;31). It is generally accepted that the antibodies produced 
locally, especially SIgA, are of major importance in the resistance to influenza 
disease. The HAI test provides a surrogate correlate of protection and titres of ≥40 are 
protective against influenza (48). In the present studies we have used the locally and 
systemically produced antibody concentrations and the HAI-test to show vaccine 
efficacy. In all our studies included in this thesis the antibody levels were comparable 
to our earlier studies (17;32;34). The present studies have mainly measured the total 
influenza specific immunoglobulin (antibody) concentrations (IgX), without sub-
typing the different Ig classes or subclasses. We have however not examined the 
efficacy of the vaccine to protect from influenza disease in our studies. Those kind of 
studies require a completely different experimental set-up, e.g. larger cohort, follow 
up and registration of other parameters like side effects, burden of influenza in the 
communities etc.         
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2.4.2 Antibody secreting cell (ASC) response 
Antibodies are produced and secreted by many differential stages of B-lymphocytes 
(ASC), but the antibodies are particularly secreted by terminally differentiated plasma 
cells. In previous studies it has been demonstrated that there is an early influenza 
specific ASC response in the blood and in the tonsils after parenteral influenza 
vaccination (17;26). We have in our studies found data supporting these earlier 
observations. Animal studies of mice and pigs immunized or infected with influenza 
virus, have shown an increase of ASCs in the nasal mucosa as well as in NALT 
(55;90). Since local antibodies play a major role in resistance against influenza 
infection, we wanted to determine the effect of parenteral influenza vaccine on the 
number of ASC in the nasal mucosa. We collected blood, tonsils and nasal biopsies 
under general anaesthesia for tonsillectomy.  Due to the design of our studies and for 
medical and ethical limitations, we were not able to compare pre- and post-
vaccination responses in tonsils and nasal mucosa of an individual patient. In the first 
study (Paper I) we surprisingly found a 10-100 times higher number of influenza-
specific ASC in the nasal mucosa biopsies than in blood and tonsils, without recent 
influenza exposure. These ASCs probably have an important role in protection 
against influenza infection. In the animal studies the pre-infection and pre-
immunization numbers of the influenza-specific ASCs in the nasal mucosa were low 
and seemed to return to the basal level a short time after challenge (55;90). The 
human situation is probably reflecting previous exposure to influenza. In our next 
study (Paper II) we examined the level of ASCs in blood, tonsils and nasal biopsies 1 
week after parenteral influenza vaccination. In line with earlier results, we found a 
strong increase in the ASC level in the blood and a statistically significant increase to 
2 of the 3 vaccine strains in tonsils. In the nasal mucosa there was no change in the 
ASC level after parenterally immunization. This indicates that the parenteral 
vaccination mainly stimulates the systemic immune system with an increase in ASCs 
and antibodies in the blood, and only partly the local immune system with an increase 
in tonsillar ASCs and oral antibody concentrations, but not the nasal mucosa. The 
high numbers of influenza specific ASCs in the nasal mucosa probably remain stable 
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for a long period of time, but may decline over years without local stimulation, e.g. a 
new influenza infection.  
2.4.3 Lymphoid cells in tonsils 
We wanted to examine in more detail the lymphoid cells in the tonsils. We knew 
from our earlier studies that the number of influenza-specific ASC is increasing in 
tonsillar tissue one week after vaccination. To investigate if there are other changes in 
the cellular pattern (Paper III), we used tonsils from both vaccinated and non-
vaccinated patients, and examined cryosectioned tonsillar tissue stained with 
monoclonal antibodies for 14 human cell surface antigens representing the major 
types of cells of the immune system. We did not expect there would be any 
significant difference between the vaccinated and the non-vaccinated. This method of 
enumerating positively stained cells in complex tissue samples should not be 
compared with a more sophisticated method like flow cytometry. We have been extra 
careful in interpreting the tissue staining results from this study. For most cell 
markers there were no significant changes between the two groups. One of the pivotal 
cells in the immune system is the CD4+ T-helper cell, which controls and regulates 
the immune response. We found a significant decrease in this CD4+ cell population 
in the tonsils of the vaccinated patients. CD4+ cells are also the main contributors to 
the CD45 RA (naïve T-cells) and CD45 RO (memory T-cells) positive cells, which 
were also found at a significantly lower frequency in the vaccinated patients. A 
British study which examined tonsillar tissue from vaccinated and non-vaccinated 
patients, found that there is a shift in the CD4+ cell population from mixed 
CD45RA+ and CD45RO+ population to an almost exclusively CD45RO+ population 
(44). We can only speculate on the reason for this drop in T-helper cells after 
vaccination. The Th-cells may be recruited to local draining lymph nodes in the 
systemic compartment of the immune system, contributing to the immune response to 
the vaccine. In the immunohistochemical staining of the tonsillar tissue we also 
observed a significant increase in CD68 positive cells, as a marker for macrophages.  
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Another macrophage marker, MAC387 did not change. The reason for this is difficult 
to explain, and our results must be interpreted with caution. It might be that these two 
markers represent different subsets of macrophages. However, both of these markers 
are not exclusively specific for macrophages (37;39;72).   
In paper III we also used an alternative method to detect the influenza specific ASC 
in tonsillar tissue. We stained fixed tonsillar tissue sections with fluorescent labelled 
H3N2 influenza antigen. As shown by the ELISPOT method on tonsillar 
lymphocytes in culture, we were able to show a significant increase in influenza 
specific ASC of the vaccinated patients. The ASCs were found scattered around as 
individual cells in the tonsillar tissue, especially around the germinal centres and 
mantle zones, but also outside the follicles. We believe this is as an indication on that 
the ASCs are homing to the tonsils from the bloodstream, rather than being locally 
activated. This novel method of in situ (tissue) detection with immunofluorescent 
labelled ASC has to our knowledge, not been described earlier. 
2.4.4 Cyto- and chemokines 
Cytokines are small protein molecules which are produced and secreted by mainly 
immune competent cells as a way of communication. They are mediators that interact 
with receptors on other cells, and regulate the immune responses in different ways. 
Some cytokines attract cells to the site of the immune response, so called chemo 
attractant cytokines or chemokines. Cytokines do not only mediate the 
communication between different cells, but may themselves contribute to the 
symptoms and the pathology of the immune response.     
We have in our studies of lymphocytes from blood and tonsils shown that parenteral 
influenza vaccination has an impact on the number of immune potent cells. In our 
two trials included in paper IV, we wanted to investigate if the complex immune 
reaction to influenza vaccine could be determined in more detail, by examining the 
cytokines and chemokines involved in this process, both locally and systemically. 
Our patients were randomised into 3 groups: one control group of non-vaccinated 
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patients and two groups who were immunized 1 week or 2 weeks before the 
operation. We analysed 25 cytokines directly in unstimulated serum and saliva 
samples from all patients, 1 or 2 weeks before tonsillectomy and at the time of 
operation. This was done with a multiplex bead immuno assay that analysed 25 
different cytokines simultaneously using xMAP technology in a Luminex 100 
instrument. Generally the levels of cytokines in these samples were low, and mostly 
below detection limit. Surprisingly, the cytokine concentrations were higher in saliva 
than in serum. There was a large individual variation in the cytokine levels. Except 
for the cytokine IL-12p40 there was no significant differences in the cytokine levels 
between the groups. IL-12p40 decreased in all 3 groups at the time of the operation, 
compared with the level 1 or 2 weeks before, so we believe that this change may be 
related to stress from the operation due to neuroendocrine mediators (Reviewed in 
(35).   
The supernatants from stimulated lymphocytes from peripheral blood (PBMC) and 
tonsils (TMC) were analysed with a 10-plex cytokine assay in the Luminex 100 
instrument. We found a significant increase in INF-γ, IL-10 and TNF-α in both TMC 
and PBMC in patients vaccinated both one and two weeks earlier. Two weeks after 
vaccination there were significant increases in the levels of GM-CSF, IL-2, IL-5, IL-6 
and IL-8 in either PBMC, TMC or both. Generally there were higher cytokine 
concentrations in the TMC than in the PBMC. In an elderly and also a young 
population increases were found in the INF-γ, IL-10 and IL-6 production in 
stimulated PBMCs after vaccination (8), and there was generally a higher production 
in the young population. IL-4 was found in very low concentrations in all groups, 
which is line with a previous report form Guthrie et al (44). It has been shown earlier 
that there is limited correlation between serum cytokine levels and PBMC cytokine 
production (51), as shown in our study.    
We also examined the gene expression by QPCR of 10 cytokines in PBMC, by 
collecting whole blood in PAXgene tubes, which preserves the mRNA expression 
levels. This showed only a slight increase in most cytokines after vaccination, except 
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for IL5 and IL10, which were below the detection limit. For some cytokines (IL-2, 
IL-4, INF-γ and TGF-β) the gene expression levels were higher 1 week after 
vaccination than 2 weeks after. This may indicate that there is still some enhanced 
gene expression, but that the cytokine production is no longer activated. This 
supports the cytokine results from serum and saliva, that there is no extensive 
cytokine production at 1 or 2 weeks after influenza vaccination that can be measured 
without in vitro stimulation.   
2.5 Conclusions and Future perspectives 
This study is a continuation of a long term project by the co-authors (16-18;24;26;32-
34), but with focus on the local immune system in the upper airway mucosa and 
lymphoid tissue of humans.  
There has been a tremendous interest in influenza research in recent years due to the 
appearance of highly pathogenic avian influenza stains. This has also increased the 
focus on the next pandemic influenza and the prophecies for this are somewhat 
ominous, regarding morbidity, mortality, socio-economic implications and also our 
possibilities for prevention. 
The most effective way to protect from influenza is by vaccination. Resistance 
against influenza virus infection and illness is mediated through a complicated 
network of immune reactions, including both the innate and the adaptive immune 
systems (25;27).  
Influenza infects the respiratory mucosa in humans. The humoral immunity mediated 
mainly by SIgA in the upper respiratory tract and by IgG in the lower airways, can 
protect against influenza infection and is therefore of major importance in resistance. 
Cellular immunity mediated mainly by CTL’s (T-cells) is important in clearance of 
influenza infection and in the avoidance of complications, but it does not prevent 
infection. It is likely that lymphoid organs in the upper airways contribute 
 61
significantly to the local protection against influenza as inductive, effector and 
memory sites near the target of influenza virus infection.  
 
Figure 9. A simplified overview of the immunological processes occurring in connection 
with parenteral influenza vaccination. From (25). The injected influenza antigens are 
transported either as free antigen or by antigen presenting cells (dendritic cells) to the local 
draining lymph nodes in the armpit. The initial immune reaction is measurable in blood as 
elevated influenza specific antibodies and antibody secreting cells (ASC) [Paper I, II, III, 
IV]. Influenza specific ASC migrate to local lymphoid organs like the tonsils in the 
Waldeyer’s ring, but not to the nasal mucosa [Paper I, II]. The origin of the antibodies in 
saliva may originate from local lymphoid tissue in the oral cavity. T-helper cells may 
migrate back from tonsils to the draining lymph nodes in the armpit, participating in the 
present immune response [Paper III]. 
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Our studies have shown that vaccination with a trivalent sub-unit influenza vaccine 
induces a rapid and strong local and systemic antibody response (Fig.9). These 
antibodies are produced by ASC’s. We have found a significant up-regulation of 
influenza specific ASC’s after vaccination in tonsils and serum. In the nasal mucosa 
there are high numbers of influenza specific ASC’s, but this does not increase after 
parenteral vaccination. The importance of tonsillar tissue in the resistance to 
influenza has been questioned (100), but we have found that vaccination induces an 
upregulation of ASC’s and a reduction of CD4+ T-cells in tonsils. Although ENT-
surgeons world-wide largely spend their working days removing this immune 
competent tissue, there is little doubt that the tonsils are contributing to the immune 
response and resistance towards influenza. 
For future work there is still a tremendous amount of “unexplored land”. The 
influenza virus is unpredictable, and there is a need for more knowledge in 
understanding the interactions between the immune system and the virus. With better 
knowledge, it will be possible to develop more efficient strategies for preventing and 
treating influenza.  
The immunological effects of a live attenuated influenza vaccine administered as a 
nasal spray would be very interesting to study. Probably this route of vaccination will 
give a stronger immune response in the nasal mucosa. It would also be interesting to 
study further cellular changes in the human nasal mucosa, with reference to influenza 
vaccination locally and/or systemically. Further studies with different time-points of 
the cytokine response in the human upper airway are also needed to clarify in which 
way they contribute in the immune response. The rapid development of sophisticated 
tools for immunological studies will probably open new possibilities in examining the 
immune response of influenza vaccines.   
We hope our results will contribute to the understanding of immunity in the upper 
airway and the immune response to influenza vaccination, and also help in the 
development of better vaccine strategies for the future. 
 63
References 
 
 1.  Economic and Social Impact of Epidemic and Pandemic Influenza. Vaccine 
2006;24(44-46):6776-8. 
 2.  Andre antivirale midler. Norsk legemiddelhåndbok. 2007. 
 3.  Alho OP, Koivunen P, Penna T, Teppo H, Koskela M, Luotonen J. Tonsillectomy 
versus watchful waiting in recurrent streptococcal pharyngitis in adults: randomised 
controlled trial. BMJ 2007;334(7600):939. 
 4.  Barry J. The great influenza : the epic story of the deadliest plague in history / John 
M. Barry. Viking, New York; 2004. 
 5.  Behrens G, Stoll M. Pathogenesis and Immunology. In: Kamps B, Hoffmann C, 
Preiser W, editors. Influenza Report. Paris, Cagliari, Wuppertal, Sevilla: Flying 
Publisher; 2006. p. 92-109. 
 6.  Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD et al. Avian 
influenza A (H5N1) infection in humans. N.Engl.J Med. 2005;353(13):1374-85. 
 7.  Bergsaker M, Hungnes O, Iversen B. [Vaccination against influenza--why, for whom 
and with which vaccine?]. Tidsskr.Nor Laegeforen. 2006;126(21):2814-7. 
 8.  Bernstein ED, Gardner EM, Abrutyn E, Gross P, Murasko DM. Cytokine production 
after influenza vaccination in a healthy elderly population. Vaccine 
1998;16(18):1722-31. 
 9.  Bernstein JM, Baekkevold ES, Brandtzaeg P. Immunobiology of the Tonsils and 
Adenoids. In: Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, Mayer 
L, editors. Mucosal immunology. 3rd. ed. Elsevier Academic Press; 2005. p. 1547-
72. 
 10.  Beveridge WI. The chronicle of influenza epidemics. Hist Philos.Life Sci. 
1991;13(2):223-34. 
 11.  Bock A, Popp W, Herkner KR. Tonsillectomy and the immune system: a long-term 
follow up comparison between tonsillectomized and non-tonsillectomized children. 
Eur.Arch.Otorhinolaryngol. 1994;251(7):423-7. 
 12.  Brandtzaeg P. Immunology of tonsils and adenoids: everything the ENT surgeon 
needs to know. International Journal of Pediatric Otorhinolaryngology 
2003;67(Supplement 1):S69-S76. 
 13.  Brandtzaeg P. Role of mucosal immunity in influenza. Dev.Biol.(Basel) 
2003;115:39-48. 
 64 
 14.  Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for 
control in health care settings. Clin.Infect.Dis. 2003;37(8):1094-101. 
 15.  Brokstad KA. Qualitative, quantitative and kinetic aspects of the humoral immune 
response induced systemically and locally after influenza vaccination / Karl Albert 
Brokstad. 1995. 
 16.  Brokstad KA, Cox RJ, Major D, Wood JM, Haaheim LR. Cross-reaction but no 
avidity change of the serum antibody response after influenza vaccination. Vaccine 
1995;13(16):1522-8. 
 17.  Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR. Parenteral influenza 
vaccination induces a rapid systemic and local immune response. J Infect.Dis. 
1995;171(1):198-203. 
 18.  Brokstad KA, Cox RJ, Oxford JS, Haaheim LR. IgA, IgA subclasses, and secretory 
component levels in oral fluid collected from subjects after parental influenza 
vaccination. J Infect.Dis. 1995;171(4):1072-4. 
 19.  Brydon EW, Morris SJ, Sweet C. Role of apoptosis and cytokines in influenza virus 
morbidity. FEMS Microbiol.Rev 2005;29(4):837-50. 
 20.  Burls A, Jordan R, Barton P, Olowokure B, Wake B, Albon E et al. Vaccinating 
healthcare workers against influenza to protect the vulnerable--Is it a good use of 
healthcare resources?: A systematic review of the evidence and an economic 
evaluation. Vaccine 2006;24(19):4212-21. 
 21.  Burton MJ, Towler B, Glasziou P. Tonsillectomy versus non-surgical treatment for 
chronic / recurrent acute tonsillitis. Cochrane.Database.Syst.Rev 2000(2):CD001802. 
 22.  Cheung T, Poon L. Biology of Influenza A Virus. Annals of the New York Academy 
of Sciences 2007;1102(1):1-25. 
 23.  Cinti S. Pandemic influenza: are we ready? Disaster.Manag.Response 2005;3(3):61-
7. 
 24.  Cox RJ, Brokstad KA. The postvaccination antibody response to influenza virus 
proteins. APMIS 1999;107(3):289-96. 
 25.  Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. 
Comparison of the immune response to inactivated and live, attenuated influenza 
vaccines. Scand.J.Immunol. 2004;59(1):1-15. 
 26.  Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, Oxford JS. An 
early humoral immune response in peripheral blood following parenteral inactivated 
influenza vaccination. Vaccine 1994;12(11):993-9. 
 27.  Cox RJ, Haaheim LR, Ericsson JC, Madhun AS, Brokstad KA. The humoral and 
cellular responses induced locally and systemically after parenteral influenza 
vaccination in man. Vaccine 2006;24(44-46):6577-80. 
 65
 28.  De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Lowenadler B et al. 
Improved design and intranasal delivery of an M2e-based human influenza A 
vaccine. Vaccine 2006;24(44-46):6597-601. 
 29.  Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for 
immunology. Nat Immunol 2006;7(5):449-55. 
 30.  Doyle WJ, Gentile DA, Skoner DP. Viral and bacterial rhinitis. Clin.Allergy 
Immunol 2007;19:177-95. 
 31.  El Madhun AS. Characteristics of the humoral immune response after parenteral 
influenza vaccination / Abdullah Sami El-Madhun. 1998. 
 32.  El Madhun AS, Cox RJ, Haaheim LR. The effect of age and natural priming on the 
IgG and IgA subclass responses after parenteral influenza vaccination. J Infect.Dis. 
1999;180(4):1356-60. 
 33.  El Madhun AS, Cox RJ, Seime A, Sovik O, Haaheim LR. Systemic and local 
immune responses after parenteral influenza vaccination in juvenile diabetic patients 
and healthy controls: results from a pilot study. Vaccine 1998;16(2-3):156-60. 
 34.  El Madhun AS, Cox RJ, Soreide A, Olofsson J, Haaheim LR. Systemic and mucosal 
immune responses in young children and adults after parenteral influenza 
vaccination. J Infect.Dis. 1998;178(4):933-9. 
 35.  Elenkov IJ, Chrousos GP, Wilder RL. Neuroendocrine regulation of IL-12 and TNF-
alpha/IL-10 balance. Clinical implications. Ann.N.Y.Acad.Sci. 2000;917:94-105. 
 36.  Etchart N, Baaten B, Andersen SR, Hyland L, Wong SY, Hou S. Intranasal 
immunisation with inactivated RSV and bacterial adjuvants induces mucosal 
protection and abrogates eosinophilia upon challenge. Eur.J Immunol 
2006;36(5):1136-44. 
 37.  Falini B. PG-M1: a new monoclonal antibody directed against a fixative-resistant 
epitope on the macrophage-restricted form of the CD68 molecule. The American 
journal of pathology 1993;142(5):1359-72. 
 38.  Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G et al. Prevention 
and control of influenza. Recommendations of the Advisory Committee on 
Immunization Practices (ACIP), 2007. MMWR Recomm.Rep. 2007;56(RR-6):1-54. 
 39.  Flavell DJ, Jones DB, Wright DH. Identification of tissue histiocytes on paraffin 
sections by a new monoclonal antibody. J.Histochem.Cytochem. 1987;35(11):1217-
26. 
 40.  Ghendon Y. The immune response to influenza vaccines. Acta Virol 1990;34(3):295-
304. 
 41.  Ghendon Y. Introduction to pandemic influenza through history. Eur.J Epidemiol. 
1994;10(4):451-3. 
 66 
 42.  Glezen WP. Serious morbidity and mortality associated with influenza epidemics. 
Epidemiologic Reviews 1982;4:25-44. 
 43.  Gorfien JL. Comparison of the microanatomical distributions of macrophages and 
dendritic cells in normal and diseased tonsils. The Annals of otology, rhinology & 
laryngology 2001;110(2):173-82. 
 44.  Guthrie T. Parenteral influenza vaccination influences mucosal and systemic T cell-
mediated immunity in healthy adults. J Infect Dis 2004;190(11):1927-35. 
 45.  Haley PJ. Species differences in the structure and function of the immune system. 
Toxicology 2003;188(1):49-71. 
 46.  Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic 
cytokine responses during experimental human influenza A virus infection. Relation 
to symptom formation and host defense. J Clin.Invest 1998;101(3):643-9. 
 47.  Hiepe F, Radbruch A. Is long-term humoral immunity in the mucosa provided by 
long-lived plasma cells? A question still open. European journal of immunology 
2006;36(5):1068-9. 
 48.  Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum 
haemagglutination-inhibiting antibody in protection against challenge infection with 
influenza A2 and B viruses. J.Hyg.(Lond) 1972;70(4):767-77. 
 49.  Hoeven A, Scholing M, Wever P, Fijnheer R, Hermans M, Schneeberger P. Lack of 
Discriminating Signs and Symptoms in Clinical Diagnosis of Influenza of Patients 
Admitted to the Hospital. Infection 2007;35(2):65-8. 
 50.  Hsu APP, Tan KL, Tan YB, Han HJ, Lu PKS. Benefits and efficacy of tonsillectomy 
for recurrent tonsillitis in adults. Acta Oto-Laryngologica 2007;127(1):62-4. 
 51.  Jason J, Archibald LK, Nwanyanwu OC, Byrd MG, Kazembe PN, Dobbie H et al. 
Comparison of serum and cell-specific cytokines in humans. Clin.Diagn.Lab 
Immunol. 2001;8(6):1097-103. 
 52.  Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for 
preventing influenza in healthy adults. Cochrane.Database.Syst.Rev 
2007(2):CD001269. 
 53.  Jung KY, Lim HH, Choi G, Choi JO. Age-related changes of IgA immunocytes and 
serum and salivary IgA after tonsillectomy. Acta Otolaryngol.Suppl 1996;523:115-9. 
 54.  Lamb RA, Krug RM. Orthomyxoviridae: The Viruses and Their Replication. In: 
Knipe DM, Howley PM, editors. Fields' virology. 4 ed. Philadelphia: Lippincott 
Williams & Wilkins; 2001. p. 1487-531. 
 55.  Larsen DL, Karasin A, Zuckermann F, Olsen CW. Systemic and mucosal immune 
responses to H1N1 influenza virus infection in pigs. Veterinary Microbiology 
2000;74(1-2):117-31. 
 67
 56.  Liang B, Hyland L, Hou S. Nasal-Associated Lymphoid Tissue Is a Site of Long-
Term Virus-Specific Antibody Production following Respiratory Virus Infection of 
Mice. J.Virol. 2001;75(11):5416-20. 
 57.  Marshall T. A review of tonsillectomy for recurrent throat infection. Br.J Gen Pract. 
1998;48(431):1331-5. 
 58.  Minne A, Louahed J, Mehauden S, Baras B, Renauld JC, Vanbever R. The delivery 
site of a monovalent influenza vaccine within the respiratory tract impacts on the 
immune response. Immunology 2007;122(3):316-25. 
 59.  Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, 
Weintraub E et al. The annual impact of seasonal influenza in the US: Measuring 
disease burden and costs. Vaccine 2007;25(27):5086-96. 
 60.  Møller P. Veileder for fagområdet Øre-nese-hals-sykdommer / Norsk oto-
laryngologisk forening ; hovedredaktør: Per Møller. 1998. 
 61.  Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and 
symptoms predicting influenza infection. Arch.Intern.Med. 2000;160(21):3243-7. 
 62.  Mui SM, Rasgon BMM, Hilsinger RLJ. Efficacy of Tonsillectomy for Recurrent 
Throat Infection in Adults. [Article]. Laryngoscope 1998;108(9):1325-8. 
 63.  Nasjonalt Folkehelsehelseinstitutt. Fakta om influenza.  29-5-2007. www.fhi.no 
 
 64.  National Institute for Clinical Excellence. Guidance on the use of zanamivir, 
oseltamivir and amantadine for the treatment of influenza.  2003. www.nice.org.uk  
 
 65.  Nave H, Gebert A, Pabst R. Morphology and immunology of the human palatine 
tonsil. Anat.Embryol.(Berl) 2001;204(5):367-73. 
 66.  Ogra PL. Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody 
response to poliovirus. The New England journal of medicine 1971;284(2):59-64. 
 67.  Olofsson K. The surface epithelium of recurrent infected palatine tonsils is rich in 
gammadelta T cells. Clinical and experimental immunology 1998;111(1):36-47. 
 68.  Ostergaard PA. IgA levels and carrier rate of pathogenic bacteria in 27 children 
previously tonsillectomized. Acta Pathol.Microbiol.Scand.[C.] 1977;85(3):178-86. 
 69.  Paradise JL, Bluestone CD, Bachman RZ, Colborn DK, Bernard BS, Taylor FH et al. 
Efficacy of tonsillectomy for recurrent throat infection in severely affected children. 
Results of parallel randomized and nonrandomized clinical trials. N.Engl.J Med. 
1984;310(11):674-83. 
 70.  Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. Measurement of the mutation 
rates of animal viruses: influenza A virus and poliovirus type 1. J Virol. 
1986;59(2):377-83. 
 71.  Perry M, Whyte A. Immunology of the tonsils. Immunol Today 1998;19(9):414-21. 
 68 
 72.  Pulford KA, Rigney EM, Micklem KJ, Jones M, Stross WP, Gatter KC et al. KP1: a 
new monoclonal antibody that detects a monocyte/macrophage associated antigen in 
routinely processed tissue sections. J Clin Pathol 1989;42(4):414-21. 
 73.  Rimmelzwaan GF, Boon AC, Voeten JT, Berkhoff EG, Fouchier RA, Osterhaus AD. 
Sequence variation in the influenza A virus nucleoprotein associated with escape 
from cytotoxic T lymphocytes. Virus Res. 2004;103(1-2):97-100. 
 74.  Rivetti D, Jefferson T, Thomas R, Rudin M, Rivetti A, Di Pietrantonj C et al. 
Vaccines for preventing influenza in the elderly. Cochrane.Database.Syst.Rev 
2006;3:CD004876. 
 75.  Ruef C. Diagnosing influenza--clinical assessment and/or rapid antigen testing? 
Infection 2007;35(2):49-50. 
 76.  Russell MW, Bobek LA, Brock JH, Hajishengallis G, Tenovuo J. Innate Humoral 
Defence Factors. Mucosal immunology / edited by Jiri Mestecky ... [et al.].-3rd ed. 
2005. p. 73-93. 
 77.  Ryan J, Zoellner Y, Gradl B, Palache B, Medema J. Establishing the health and 
economic impact of influenza vaccination within the European Union 25 countries. 
Vaccine 2006;24(47-48):6812-22. 
 78.  Sainz M, Gutierrez F, Moreno PM, Munoz C, Ciges M. Changes in immunologic 
response in tonsillectomized children. I. Immunosuppression in recurrent tonsillitis. 
Clin.Otolaryngol.Allied Sci. 1992;17(5):376-9. 
 79.  Savage DC. Microbial ecology of the gastrointestinal tract. Annu.Rev Microbiol. 
1977;31:107-33. 
 80.  Scadding GK. Immunology of the tonsil: a review. J R.Soc.Med. 1990;83(2):104-7. 
 81.  Shope RE. Swine Influenza: I. Experimental Transmission and Pathology. 
J.Exp.Med. 1931;54(3):349-59. 
 82.  Singleton R, Etchart N, Hou S, Hyland L. Inability To Evoke a Long-Lasting 
Protective Immune Response to Respiratory Syncytial Virus Infection in Mice 
Correlates with Ineffective Nasal Antibody Responses. J.Virol. 2003;77(21):11303-
11. 
 83.  Sladkova T, Kostolansky F. The role of cytokines in the immune response to 
influenza A virus infection. Acta Virol 2006;50(3):151-62. 
 84.  Smith W. A virus obtained from influenza patients.  Lancet 1933;222:66-8. 
 85.  Smith S, Demicheli V, Di Pietrantonj C, Harnden AR, Jefferson T, Matheson NJ et 
al. Vaccines for preventing influenza in healthy children. 
Cochrane.Database.Syst.Rev 2006(1):CD004879. 
 86.  Soreide AK, Olofsson J. [Tonsillectomy--day surgery or hospitalization?]. 
Tidsskr.Nor Laegeforen. 1999;119(10):1423-7. 
 69
 87.  Stech J, Xiong X, Scholtissek C, Webster RG. Independence of Evolutionary and 
Mutational Rates after Transmission of Avian Influenza Viruses to Swine. J.Virol. 
1999;73(3):1878-84. 
 88.  Suzumoto M, Hotomi M, Fujihara K, Tamura S, Kuki K, Tohya K et al. Functions of 
tonsils in the mucosal immune system of the upper respiratory tract using a novel 
animal model, Suncus murinus. Acta Otolaryngol. 2006;126(11):1164-70. 
 89.  Szucs TD. Medical economics in the field of influenza--past, present and future. 
Virus Research 2004;103(1-2):25-30. 
 90.  Tamura S, Iwasaki T, Thompson AH, Asanuma H, Chen Z, Suzuki Y et al. 
Antibody-forming cells in the nasal-associated lymphoid tissue during primary 
influenza virus infection. J Gen Virol 1998;79(2):291-9. 
 91.  Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the 
respiratory tract mucosa. Jpn.J Infect.Dis. 2004;57(6):236-47. 
 92.  The Macroepidemiology of Influenza Vaccination (MIV) Study Group. The 
macroepidemiology of influenza vaccination in 56 countries, 1997-2003. Vaccine 
2005;23(44):5133-43. 
 93.  The National Institute of Allergy and Infectious Diseases (NIAID), National 
Institutes of Health NIH. Antigenic Drift illustration.  28-5-2005. 
www3.niaid.nih.gov/news/focuson/flu/illustrations/antigenic/antigenicdrift.htm 
 
 94.  The National Institute of Allergy and Infectious Diseases (NIAID), National 
Institutes of Health NIH. Antigenic Shift illustration.  28-5-2005. 
www3.niaid.nih.gov/news/focuson/flu/illustrations/antigenic/antigenicshift.htm 
 
 95.  Thompson WW. Mortality associated with influenza and respiratory syncytial virus 
in the United States. JAMA 2003;289(2):179-86. 
 96.  Tyler KL, Nathanson N. Pathogenesis of Viral Infections. In: Knipe DM, Howley 
PM, editors. Fields' virology. 4 ed. Philadelphia: Lippincott Williams & Wilkins; 
2001. p. 199-243. 
 97.  Vajdy M, Baudner B, Del Giudice G, O'Hagan D. A vaccination strategy to enhance 
mucosal and systemic antibody and T cell responses against influenza. Clinical 
Immunology 2007;123(2):166-75. 
 98.  van Staaij BK, van den Akker EH, Rovers MM, Hordijk GJ, Hoes AW, Schilder 
AGM. Effectiveness of adenotonsillectomy in children with mild symptoms of throat 
infections or adenotonsillar hypertrophy: open, randomised controlled trial. BMJ 
2004;329(7467):651. 
 99.  Wallace LA, Collins TC, Douglas JDM, McIntyre S, Millar J, Carman WF. 
Virological surveillance of influenza-like illness in the community using PCR and 
serology. Journal of Clinical Virology 2004;31(1):40-5. 
 70 
 100.  Wiley JA, Tighe MP, Harmsen AG. Upper Respiratory Tract Resistance to Influenza 
Infection Is Not Prevented by the Absence of Either Nasal-Associated Lymphoid 
Tissue or Cervical Lymph Nodes. J Immunol 2005;175(5):3186-96. 
 101.  Wilschut J, McElhaney JE, Palache AM. Pathogenesis, Clinical Features and 
Diagnosis. In: McElhaney JE, Palache AM, editors. Rapid Reference to Influenza. 
2nd ed. Edinburgh: Mosby Elsevier; 2006. p. 96-116. 
 102.  Wilschut J, McElhaney JE, Palache AM. Social and Economical Impact of Influenza. 
In: McElhaney JE, Palache AM, editors. Rapid Reference to Influenza. 2nd ed. 
Edinburgh: Mosby Elsevier; 2006. p. 117-32. 
 103.  Wilschut J, McElhaney JE, Palache AM. The Influenza Virus: Structure and 
Replication Jan C. Wilschut,, Abraham M. Palache. In: McElhaney JE, Palache AM, 
editors. Influenza. Edinburgh: Mosby Elsevier; 2006. p. 27-48. 
 104.  Wolfensberger M, Haury JA, Linder T. Parent satisfaction 1 year after 
adenotonsillectomy of their children. International Journal of Pediatric 
Otorhinolaryngology 2000;56(3):199-205. 
 105.  World Health Organisation. A revision of the system of nomenclature for influenza 
viruses: a WHO memorandum. Bull.World Health Organ 1980;58(4):585-91. 
 106.  World Health Organisation. Influenza Fact Sheet No. 211.  2003. 
www.who.int/mediacentre/factsheets/fs211/en/index.html  
 
 107.  World Health Organisation. Cumulative Number of Confirmed Human Cases of 
Avian Influenza A/(H5N1) Reported to WHO.  30-4-2008. 
www.who.int/csr/disease/avian_influenza/country/cases_table_2008_04_30/en/index
.html 
 
 108.  Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C et al. Rapid 
cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 
2008. 
 109.  Wright PF, Webster RG. Orthomyxoviruses. In: Knipe DM, Howley PM, editors. 
Fields' virology. 4 ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1533-
79. 
 110.  Yang Y, Halloran ME, Sugimoto J, Longini JrIM. Detecting human-to-human 
transmission of avian influenza A (H5N1). Emerg Infect Dis [serial on the 
Internet].2007 Sep. Available from www.cdc.gov/EID/content/13/9/1348.htm  
 111.  Zambon M, Hays J, Webster A, Newman R, Keene O. Diagnosis of Influenza in the 
Community: Relationship of Clinical Diagnosis to Confirmed Virological, Serologic, 
or Molecular Detection of Influenza. Arch Intern Med 2001;161(17):2116-22. 
 
 
 
 71
Errata 
Paper II; Page 879, first column, 4.th line from the top, should be: In addition, a nasal 
mucosal biopsy sample from the middle portion of the caudal medial part of the 
inferior turbinate was collected from 8 patients.  
Paper IV; Page 145, reference number 9, Dinarello et al, was published in J Clin 
Invest in 1984. 
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